VIRX News and Press, Viracta Therapeutics Inc. From 11/04/21

Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting Final results from the Phase 1b/2 trial of nanatinostat and valganciclovir (Nana-val) in relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphom...

Viracta Therapeutics to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that com...

Gainers: Viracta Therapeutics (NASDAQ:VIRX) +5%. Angi (NASDAQ:ANGI) +4%. Calithera Biosciences CALA +3%. Progenity (NASDAQ:PROG) +2%. IVERIC bio (NASDAQ:ISEE) +2%. Losers: TaskUs TASK -8%. DLocal Limited (NASDAQ:DLO) -7%. EverQuote EVER -6%. TORM plc (NASDAQ:TRMD) -4%. Lim...

Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors Multinational trial expands Viracta's clinical-stage pipeline beyond EBV+ lymphoproliferative disorders PR Newswire SAN DIEGO , Oct. 6, 2021 /PRNewswire/ -- V...

Viracta Therapeutics to Present at Upcoming Investor Conferences in September PR Newswire SAN DIEGO , Sept. 7, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today anno...

Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China Viracta now controls global rights to its all-oral combination regimen of nanatinostat and valganciclovir PR Newswire SAN DIEGO , Au...

Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors PR Newswire SAN DIEGO , Aug. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology comp...

Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates Initiated NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma Received FDA clearance of IND application for a Phase 1b/2 ...

Viracta Therapeutics (VIRX) announces that the U.S. FDA has cleared Viracta's Investigational New Drug ((IND)) application to proceed into an early stage trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma ((RM-NPC)) and other EBV+ solid ...

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors Third combination trial with nanatinostat and valganciclovir broadens scope beyond EBV+ lymphoproliferative disorders Trial initiation expe...